Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis

Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bethge, Johannes, Meffert, Silvia, Ellrichmann, Mark, Conrad, Claudio, Nikolaus, Susanna, Schreiber, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306500/
https://www.ncbi.nlm.nih.gov/pubmed/28243458
http://dx.doi.org/10.1136/bmjgast-2016-000127
Descripción
Sumario:Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe. α4/β7 Expressing lymphocytes are most likely not associated in the aetiology of SpA.

Ejemplares similares